Skip to Content

ET-105 Approval Status

FDA Approved: No
Brand name: ET-105
Generic name: lamotrigine
Company: Eton Pharmaceuticals, Inc.

ET-105 is an oral liquid formulation of lamotrigine in development as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.

Development Status and FDA Approval Process for ET-105

DateArticle
Aug  1, 2019Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide